Clinicians report that early AKT inhibition side effects are manageable, allowing four out of five patients to maintain ...

The study shows semaglutide's cardiovascular benefits are more closely tied to attained dose than weight loss, challenging ...

Eli Lilly’s once-daily oral pill orforglipron outperformed oral semaglutide in reducing blood sugar and body weight over 52 ...

Certain diabetes medications - including GLP-1 drugs, metformin, and SGLT2 inhibitors - are linked to meaningfully lower ...

Background Metformin demonstrates antiepileptogenic (primary prevention) and antiseizure (symptom control) properties in ...

Researchers evaluated the efficacy of cagrilintide-semaglutide vs semaglutide alone in adults with inadequately controlled type 2 diabetes.

A new study reveals optimal ADHD medication dosages to improve symptom management while minimizing side effects for youth and ...

The most common side effects of IV lecanemab are headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of an ...

‘I’ve shrunk from a size 3XL to an extra small on weight loss drugs - and saved £4,000’ ...

Austedo and Austedo XR treat tardive dyskinesia and chorea related to Huntington’s disease in adults. The dosage varies depending on the condition. Austedo typically starts at 6 mg twice daily.

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk that is approved by the U.S. Food ...

The FDA approved orforglipron (Foundayo) on April 1, 2026, making it the first non-peptide oral GLP-1 receptor agonist ...